CJC-1295 Dosage Chart
With-DAC vs no-DAC protocols, common pairing with ipamorelin, and reconstitution math for the 2 mg vial.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
CJC-1295 is a long-acting growth-hormone-releasing hormone (GHRH) analog. It comes in two forms: 'with DAC' (Drug Affinity Complex — long half-life, sustained GH elevation) and 'no DAC' (also called Mod GRF 1-29 — short half-life, used to mimic natural pulsatile GH release). Most experienced clinicians prefer the no-DAC version paired with ipamorelin to preserve the pulsatile GH pattern that is thought to be more physiologic.
CJC-1295 at a Glance
| With DAC — typical dose | 1–2 mg subQ, 1–2× per week |
|---|---|
| No DAC (Mod GRF 1-29) — typical dose | 100 mcg subQ, 1–3× per day |
| Common pairing | No-DAC CJC-1295 + ipamorelin (typically 100 mcg of each) |
| Cycle length | 8–12 weeks on, 4 weeks off |
| Best timing | Pre-bed (90+ minutes after last meal) and/or fasted morning |
| FDA status | Not FDA-approved. Compounded; original DAC version was studied in Phase 1/2 trials but development was discontinued. |
| Source quality | Limited human pharmacokinetic data. Most protocols are practitioner-derived. |
CJC-1295 Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for CJC-1295. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 2 mg (no DAC) | 2 mL | 1 mg/mL (100 mcg per 0.1 mL) |
|
| 2 mg (with DAC) | 2 mL | 1 mg/mL |
|
| 5 mg (combination CJC/ipamorelin blend) | 2.5 mL | 2 mg/mL combined |
|
U-100 syringe reference: 100 units = 1.0 mL. So 10 units = 0.1 mL, 25 units = 0.25 mL, 50 units = 0.5 mL. Pre-mixed CJC-1295 + ipamorelin blend vials are common at compounding pharmacies — confirm the per-component concentration on your label before drawing.
CJC-1295 Dosing by Use Case
Commonly cited protocols vary by what CJC-1295 is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Pulsatile GH support (no-DAC, with ipamorelin) | 100 mcg CJC-1295 + 100 mcg ipamorelin | Pre-bed, 5–7 nights per week | 8–12 weeks | Default 'CJC/Ipa' protocol. Mimics natural overnight GH pulse. |
| Multi-dose pulsatile (no-DAC, athletic or aggressive) | 100 mcg CJC-1295 + 100 mcg ipamorelin | 2–3× daily (AM fasted, post-workout, pre-bed) | 8–12 weeks | Stronger combined GH exposure; more compliance burden. |
| Sustained GH elevation (with DAC) | 1–2 mg CJC-1295 with DAC | 1–2× per week | 8–12 weeks | Non-pulsatile; many clinicians avoid this approach because it deviates from physiologic GH release. |
Stacking CJC-1295
The dominant CJC-1295 protocol is the no-DAC version paired with ipamorelin. The pairing is so common that compounding pharmacies often supply pre-mixed CJC/Ipa blend vials. CJC-1295 with DAC is rarely stacked with ipamorelin because the sustained CJC activity defeats the pulsatile pattern that ipamorelin contributes.
CJC-1295 is generally well-tolerated at typical doses, but the with-DAC version raises concerns about non-physiologic sustained GH elevation.
- •Common side effects: injection-site reactions, mild fluid retention, transient flushing or headache, vivid dreams.
- •With-DAC concern: sustained, non-pulsatile GH elevation is not how the body normally releases GH. Long-term implications are not well-studied.
- •Theoretical concern with chronic GH elevation: insulin resistance, water retention, possible facilitation of cancer growth in patients with malignancy. Not unique to CJC-1295 — applies to all GH-releasing peptides.
- •Original CJC-1295 with DAC clinical development was discontinued; subsequent human safety data is limited.
- •Active or recent malignancy
- •Untreated hyperglycemia or poorly controlled diabetes
- •Pregnancy or breastfeeding
- •Children or adolescents (use only under specialist supervision for diagnosed GH deficiency)
CJC-1295 Dosing FAQ
DAC stands for Drug Affinity Complex, a chemical modification that extends the half-life from minutes to roughly 6–8 days. With-DAC produces sustained GH elevation; no-DAC (Mod GRF 1-29) acts in short pulses similar to natural GHRH. Most clinicians prefer no-DAC because pulsatile GH release matches normal physiology.
CJC-1295 stimulates GH release via GHRH receptors; ipamorelin stimulates the same release via the ghrelin receptor. The two pathways are synergistic — combined dosing produces a larger GH pulse than either alone, while ipamorelin selectively avoids cortisol and prolactin release that other GH secretagogues can trigger.
Pre-bed dosing (90+ minutes after the last meal, ideally on an empty stomach) is the most common single-dose schedule because it aligns with the natural overnight GH pulse during deep sleep. Multi-dose protocols add a fasted morning dose and/or post-workout dose.
Sleep quality and recovery improvements are commonly reported within 2–4 weeks. Body composition changes (lean mass, fat loss) typically take 8–12 weeks. Anti-aging or skin changes are reported over 3–6 months. None of these are clinically validated outcomes — they are practitioner-reported and patient-reported.
Sources
Related Dosage Charts
Want the full CJC-1295 guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for CJC-1295 therapy.
See CJC-1295 guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.